AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30860411 — intervention group
Group type: COMPARATOR
Intervention: SVS (same volume with both legs starting with the stronger leg)
Number of subjects: 45
Study 27353323 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin bridging
Number of subjects: 2500
Study 27353323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-pectoral location of ICD
Number of subjects: 2500
Study 27353323 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous stroke
Number of subjects: 2500
Study 27353323 — intervention group
Group type: EXPERIMENTAL
Intervention: Upgrade from permanent pacemaker
Number of subjects: 2500
Study 27353323 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2500
Study 27353323 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant pocket haematoma
Number of subjects: 2500
Study 26115880 — intervention group
Group type: EXPERIMENTAL
Intervention: LITE condition (one tai chi session twice weekly for 12 weeks)
Number of subjects: 60
Study 26115880 — intervention group
Group type: EXPERIMENTAL
Intervention: PLUS condition (one tai chi session 3 times weekly for 12 weeks, followed by maintenance classes 1-2 times weekly for an additional 12 weeks)
Number of subjects: 60
Study 26115880 — intervention group
Group type: EXPERIMENTAL
Intervention: LITE and PLUS conditions
Number of subjects: 60
Study 22967853 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary positive expiratory pressure (TPEP) combined with manually assisted breathing techniques for 10 consecutive days, twice a day for 20 minutes plus 15 minutes of TPEP.
Number of subjects: 98
Study 22967853 — intervention group
Group type: COMPARATOR
Intervention: Control group treated by manually assisted breathing techniques alone for 10 consecutive days.
Number of subjects: 98
Study 22967853 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary positive expiratory pressure (TPEP) combined with manually assisted breathing techniques.
Number of subjects: 98
Study 21681607 — intervention group
Group type: EXPERIMENTAL
Intervention: PD 0200390 administered 30 minutes earlier than standard dosing
Number of subjects: 0
Study 21681607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21681607 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 0
Study 17356554 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules (3 capsules daily containing 10^9 CFU Lactobacillus acidophilus and Bifidobacterium longum, 10-15 mg fructo-oligosaccharide)
Number of subjects: 55
Study 17356554 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (3 capsules daily)
Number of subjects: 55
Study 16950182 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of rosuvastatin
Number of subjects: 696
Study 16950182 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of atorvastatin
Number of subjects: 696
Study 16950182 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of rosuvastatin
Number of subjects: 696
Study 16950182 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of atorvastatin
Number of subjects: 696
Study 12707583 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and ultrasonography
Number of subjects: 0
Study 10676670 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU vitamin E per day
Number of subjects: 22
Study 10676670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10676670 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking controls
Number of subjects: 22
Study 9105488 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge- and cognitive-behavioral skills-building intervention
Number of subjects: 513
Study 8339135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent D-penicillamine therapy (250-750mg daily reduced to the same dose taken 1 week out of every 4)
Number of subjects: 59
Study 8339135 — intervention group
Group type: COMPARATOR
Intervention: Continuous D-penicillamine therapy
Number of subjects: 59
Study 3522630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral self-control therapy (adjunctive therapy)
Number of subjects: 0
Study 3522630 — intervention group
Group type: COMPARATOR
Intervention: Stimulant medications (standard treatment)
Number of subjects: 0
Study 30161172 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-treat intervention
Number of subjects: 63
Study 29901369 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA (150 mg injections)
Number of subjects: 28
Study 29901369 — intervention group
Group type: COMPARATOR
Intervention: Control (no DMPA injection)
Number of subjects: 28
Study 25265770 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 100
Study 25265770 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 100
Study 25265770 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (patellar tendon graft subgroup)
Number of subjects: 100
Study 25265770 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (patellar tendon graft subgroup)
Number of subjects: 100
Study 21332611 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review intervention involving clinicians, hospital management, commissioners, and patients focusing on four specific evidence-based aspects of COPD care.
Number of subjects: 0
Study 21332611 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review intervention
Number of subjects: 0
Study 21332611 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20410151 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation (standard physiotherapy and nutritional interventions plus additional rehabilitation)
Number of subjects: 16
Study 20410151 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy and nutritional interventions (control group)
Number of subjects: 16
Study 18618278 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes history
Number of subjects: 33088
Study 18618278 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes history in lean men (BMI < 25 kg/m(2))
Number of subjects: 33088
Study 18618278 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes history in physically active men (3+ hours vigorous activity/week)
Number of subjects: 33088
Study 16410276 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intensified insulin therapy (MII) using insulin pens and premixed insulin (30/70, 40/60, 50/50) in Group AI and Group AII.
Number of subjects: 125
Study 16410276 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intensified insulin therapy (MII) in Group AII.
Number of subjects: 125
Study 16410276 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy in Group B.
Number of subjects: 125
Study 12838216 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg) administered orally 15 hours and 3 hours before ERCP
Number of subjects: 1115
Study 12838216 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally 15 hours and 3 hours before ERCP
Number of subjects: 1115
Study 12838216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (corticosteroid and control)
Number of subjects: 1115
Study 10846911 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam premedication
Number of subjects: 87
Study 10846911 — intervention group
Group type: COMPARATOR
Intervention: Placebo premedication
Number of subjects: 87
Study 10846911 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 87
Study 10846911 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 87
Study 9101144 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-viewing endoscope
Number of subjects: 45
Study 9101144 — intervention group
Group type: COMPARATOR
Intervention: Side-viewing duodenoscope
Number of subjects: 45
Study 1541306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular phenobarbitone 7 mg.kg‐1
Number of subjects: 11
Study 1541306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2859779 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol
Number of subjects: 60
Study 2859779 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 2859779 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 60
Study 31219150 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) in the major histocompatibility complex class I region (MHC I)
Number of subjects: 2440
Study 31219150 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA alleles
Number of subjects: 2440
Study 28537957 — intervention group
Group type: EXPERIMENTAL
Intervention: ANtiPain intervention (n = 20)
Number of subjects: 39
Study 28537957 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group, n = 19)
Number of subjects: 39
Study 26772171 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple‐Modality and Mind‐Motor (M4) intervention group
Number of subjects: 0
Study 26772171 — intervention group
Group type: COMPARATOR
Intervention: Multiple‐Modality (M2) comparison group
Number of subjects: 0
Study 24482343 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural sign language community
Number of subjects: 2
Study 24482343 — intervention group
Group type: COMPARATOR
Intervention: Homesign systems
Number of subjects: 2
Study 24482343 — intervention group
Group type: EXPERIMENTAL
Intervention: Population of interacting individuals in simulations
Number of subjects: 2
Study 22289887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (3800 IU daily subcutaneous injections)
Number of subjects: 135
Study 22289887 — intervention group
Group type: COMPARATOR
Intervention: Medical surveillance alone
Number of subjects: 135
Study 20847190 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker treatment
Number of subjects: 25
Study 20847190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17626705 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Notification
Number of subjects: 2400
Study 17626705 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2400
Study 17626705 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk
Number of subjects: 2400
Study 17626705 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy
Number of subjects: 2400
Study 17626705 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Notification (2 weeks)
Number of subjects: 2400
Study 15064424 — intervention group
Group type: EXPERIMENTAL
Intervention: CPTPPR
Number of subjects: 7
Study 15064424 — intervention group
Group type: COMPARATOR
Intervention: CPT+15%
Number of subjects: 7
Study 11447078 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mL black tea
Number of subjects: 66
Study 11447078 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mL black tea daily for 4 weeks
Number of subjects: 66
Study 11447078 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 66
Study 11447078 — intervention group
Group type: COMPARATOR
Intervention: 200 mg caffeine (equivalent oral dose)
Number of subjects: 66
Study 9508353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ferrum Hausmann (iron dextrin)
Number of subjects: 0
Study 9508353 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous fumarate
Number of subjects: 0
Study 8293316 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg tyrosine
Number of subjects: 16
Study 8293316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3191659 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 30
Study 31978591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel rectal spacer
Number of subjects: 222
Study 31978591 — intervention group
Group type: COMPARATOR
Intervention: Control plans (no spacer)
Number of subjects: 222
Study 31542768 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-aligning prosthesis
Number of subjects: 90
Study 31542768 — intervention group
Group type: COMPARATOR
Intervention: Standard (more rigid) prosthesis
Number of subjects: 90
Study 28320561 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine solution
Number of subjects: 114
Study 28320561 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine solution
Number of subjects: 114
Study 25878639 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine
Number of subjects: 120
Study 25878639 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine
Number of subjects: 120
Study 22933432 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing and counseling
Number of subjects: 108
Study 22933432 — intervention group
Group type: COMPARATOR
Intervention: Control (no genetic testing)
Number of subjects: 108
Study 21689356 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative mechanical bowel preparation (4 l of polyethylene glycol) plus a glycerine 5% enema (2 l)
Number of subjects: 229
Study 21689356 — intervention group
Group type: COMPARATOR
Intervention: Single glycerine 5% enema (2 l)
Number of subjects: 229
Study 18087660 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg risedronate on two consecutive days each month (2CDM)
Number of subjects: 1229
Study 18087660 — intervention group
Group type: COMPARATOR
Intervention: 5 mg daily risedronate
Number of subjects: 1229
Study 17078437 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the Back‐Shu and Front‐Mu points plus oral decoction
Number of subjects: 36
Study 17078437 — intervention group
Group type: COMPARATOR
Intervention: Oral decoction alone
Number of subjects: 36
Study 15274173 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg escitalopram
Number of subjects: 839
Study 15274173 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram
Number of subjects: 839
Study 15274173 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram
Number of subjects: 839
Study 15274173 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 839
Study 15274173 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (5 mg, 10 mg, 20 mg escitalopram and 20 mg paroxetine)
Number of subjects: 839
Study 15274173 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (5-20 mg)
Number of subjects: 839
Study 15274173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 839
Study 11400897 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical extirpation (Group I)
Number of subjects: 79
Study 11400897 — intervention group
Group type: COMPARATOR
Intervention: High-energy extracorporeal shock wave therapy (Group II)
Number of subjects: 79
Study 9003206 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micrograms twice daily
Number of subjects: 228
Study 9003206 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol, 200 micrograms four times daily
Number of subjects: 228
Study 7685685 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac/misoprostol 50mg/200 micrograms
Number of subjects: 670
Study 7685685 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 50mg
Number of subjects: 670
Study 2892258 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 150 mg B.D.
Number of subjects: 275
Study 2892258 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg nocte
Number of subjects: 275
Study 2892258 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg B.D.
Number of subjects: 275
Study 31790779 — intervention group
Group type: EXPERIMENTAL
Intervention: Unyvero i60 ITI multiplex PCR (mPCR)
Number of subjects: 50
Study 31790779 — intervention group
Group type: COMPARATOR
Intervention: Standard bacteriology
Number of subjects: 50
Study 31495379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightlife Safety Plans (NSP)
Number of subjects: 959
Study 31495379 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 959
Study 28681715 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tRNS of M1
Number of subjects: 20
Study 28681715 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study 24750780 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone foam dressings applied to the sacrum and heels, changed every 3 days in the ICU.
Number of subjects: 440
Study 24750780 — intervention group
Group type: COMPARATOR
Intervention: Standard PU prevention care during ED and ICU stay.
Number of subjects: 440
Study 23649818 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological allograft (group A)
Number of subjects: 40
Study 23649818 — intervention group
Group type: COMPARATOR
Intervention: Synthetic ligament (group B)
Number of subjects: 40
Study 22120091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 117
Study 22120091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 117
Study 22120091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 45 mg
Number of subjects: 117
Study 22120091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 19591515 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine ODT 12.5 mg administered after a high-fat/calorie breakfast
Number of subjects: 24
Study 19591515 — intervention group
Group type: COMPARATOR
Intervention: Clozapine ODT 12.5 mg administered in a fasted state
Number of subjects: 24
Study 16481384 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 16481384 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-vindesine
Number of subjects: 0
Study 14566480 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist skin care with 3% urea lotion
Number of subjects: 88
Study 14566480 — intervention group
Group type: COMPARATOR
Intervention: Conventional dry skin care
Number of subjects: 88
Study 10712990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (caloric supplementation for at least 2 weeks)
Number of subjects: 9
Study 10712990 — intervention group
Group type: COMPARATOR
Intervention: Control (no nutritional support)
Number of subjects: 9
Study 9021362 — intervention group
Group type: EXPERIMENTAL
Intervention: FSP + DNB speculum (group B, n = 110)
Number of subjects: 104
Study 9021362 — intervention group
Group type: COMPARATOR
Intervention: IUI (group A, n = 92)
Number of subjects: 104
Study 7505130 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of hepatitis vaccine
Number of subjects: 28
Study 7505130 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of hepatitis vaccine
Number of subjects: 28
Study 7505130 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis vaccine (single or double dose)
Number of subjects: 28
Study 7505130 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose vaccine with revaccination if titer is negative or insufficiently high
Number of subjects: 28
Study 3920170 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 71
Study 3920170 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 71
Study 3920170 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 71
Study 29035942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral renal denervation (RDN) using therapeutic levels of ultrasound energy
Number of subjects: 81
Study 29035942 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment with bilateral application of diagnostic levels of ultrasound energy
Number of subjects: 81
Study 27505217 — intervention group
Group type: EXPERIMENTAL
Intervention: High construal level prime with visual cue reminder
Number of subjects: 176
Study 27505217 — intervention group
Group type: EXPERIMENTAL
Intervention: High construal level prime without visual cue reminder
Number of subjects: 176
Study 27505217 — intervention group
Group type: COMPARATOR
Intervention: Low construal level prime with visual cue reminder
Number of subjects: 176
Study 27505217 — intervention group
Group type: COMPARATOR
Intervention: Low construal level prime without visual cue reminder
Number of subjects: 176
Study 24479729 — intervention group
Group type: EXPERIMENTAL
Intervention: PhysioDirect service
Number of subjects: 0
Study 22580070 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 0
Study 22580070 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 0
Study 22580070 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 20930343 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture cleanser only
Number of subjects: 24
Study 20930343 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture cleanser and mouth rinse
Number of subjects: 24
Study 18583545 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% alcohol-by-volume drink
Number of subjects: 32
Study 18583545 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% alcohol-by-volume drink
Number of subjects: 32
Study 16208640 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (specifics not provided)
Number of subjects: 0
Study 12173797 — intervention group
Group type: EXPERIMENTAL
Intervention: InspirEase holding chamber
Number of subjects: 8
Study 12173797 — intervention group
Group type: COMPARATOR
Intervention: E‐Z Spacer holding chamber
Number of subjects: 8
Study 12507025 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 80
Study 12507025 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 80
Study 9732168 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol (50 microgram/g) applied twice daily
Number of subjects: 19
Study 9732168 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied twice daily
Number of subjects: 19
Study 7995005 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ordinary-release theophylline
Number of subjects: 10
Study 7995005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3194866 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 1200 micrograms daily
Number of subjects: 18
Study 3194866 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 12.5 mg daily
Number of subjects: 18
Study 3194866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 18
Study 31714986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid (180 mg)
Number of subjects: 779